First-line treatment and overall survival in EGFR mutation-positive advanced non-small cell lung cancer: a national cohort study

被引：1

作者：

Huang, L. -y. ^{[1
]}

Chang, H. -p. ^{[2
]}

Chang, R. -y. ^{[1
]}

Tai, H. -y. ^{[2
]}

Huang, Y. -w. ^{[2
]}

Lee, P. -c. ^{[2
,3
]}

机构：

[1] Ctr Drug Evaluat, Div Hlth Technol Assessment, Taipei, Taiwan

[2] Minist Hlth & Welf, Natl Hlth Insurance Adm, Taipei, Taiwan

[3] Natl Cheng Kung Univ, Coll Med, Surg Dept, Tainan, Taiwan

来源：

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES | 2022年 / 26卷 / 20期

关键词：

Non-Squamous non-small cell lung cancer; Adenocar-cinoma; Tyrosine kinase inhibitor; Epidermal growth fac-tor receptor; Overall survival; GROWTH-FACTOR RECEPTOR;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

OBJECTIVE: Non-squamous non -small cell lung cancer (NSCLC) is the first leading cause of cancer-related deaths in Taiwan. This study aimed at evaluating the effectiveness of first-line targeted therapy for advanced epidermal growth factor receptor (EGFR) mutation-positive non-squamous NSCLC in Taiwan. PATIENTS AND METHODS: This was a re-al-world, retrospective, observational study of patients diagnosed with advanced non-squamous NSCLC (N=63,248). Between 2011 and 2019, 19,458 patients received targeted therapy and 22,994 patients received chemotherapy alone; between 2002 and 2010, 20,796 patients received chemotherapy alone. Overall survival (OS) was determined. RESULTS: The median OS for patients treated with first-line targeted therapy (22.9 months) was longer than that of patients receiving chemotherapy alone (11.7 months). HR: 0.521, log -rank test, p < 0.001. CONCLUSIONS: These data represent the potential survival outcomes of Taiwanese patients with advanced EGFR mutation-positive non-squamous NSCLC in clinical practice.

引用

页码：7632 / 7640

页数：9

共 50 条

[41] EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non-Small Cell Lung Cancer in Germany: An Observational Study [J].

Schuette, Wolfgang ;

Schirmacher, Peter ;

Eberhardt, Wilfried Ernst Erich ;

Fischer, Juergen R. ;

von der Schulenburg, J-Matthias Graf ;

Mezger, Joerg ;

Schumann, Christian ;

Serke, Monika ;

Zaun, Silke ;

Dietel, Manfred ;

Thomas, Michael .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2015, 24 (08) :1254-1261

[42] A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402) [J].

Yokoyama, Toshihide ;

Yoshioka, Hiroshige ;

Fujimoto, Daichi ;

Demura, Yoshiki ;

Hirano, Katsuya ;

Kawai, Takahiro ;

Kagami, Ryogo ;

Washio, Yasuyoshi ;

Ishida, Tadashi ;

Kogo, Mariko ;

Tomii, Keisuke ;

Okuno, Takehiro ;

Akai, Masaya ;

Hirabayashi, Masataka ;

Nishimura, Takashi ;

Nakahara, Yasuharu ;

Kim, Young Hak ;

Miyakoshi, Chisato ;

Yoshimura, Kenichi ;

Hirai, Toyohiro .

LUNG CANCER, 2019, 135 :175-180

[43] Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation [J].

Yoshimura, Naruo ;

Kudoh, Shinzoh ;

Mitsuoka, Shigeki ;

Yoshimoto, Naoki ;

Oka, Takako ;

Nakai, Toshiyuki ;

Suzumira, Tomohiro ;

Matusura, Kuniomi ;

Tochino, Yoshihiro ;

Asai, Kazuhisa ;

Kimura, Tatsuo ;

Kawaguchi, Tomoya ;

Hirata, Kazuto .

LUNG CANCER, 2015, 90 (01) :65-70

[44] Efficacy, safety and prognostic factors analysis of first-line icotinib treatment in advanced non-small cell lung cancer patients with mutated EGFR [J].

Huang, Aimi ;

Shen, Qing ;

Yu, Xiaolu ;

Wang, Huimin ;

Shi, Chunlei ;

Han, Baohui ;

Gu, Aiqin .

TRANSLATIONAL CANCER RESEARCH, 2018, 7 (03) :600-608

[45] Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040) [J].

Tomoya Fukui ;

Jiichiro Sasaki ;

Satoshi Igawa ;

Akiko Kada ;

Toshiki I. Saito ;

Yoshihito Kogure ;

Hiroaki Okamoto ;

Katsuhiko Naoki .

BMC Cancer, 22

[46] Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040) [J].

Fukui, Tomoya ;

Sasaki, Jiichiro ;

Igawa, Satoshi ;

Kada, Akiko ;

Saito, Toshiki I. I. ;

Kogure, Yoshihito ;

Okamoto, Hiroaki ;

Naoki, Katsuhiko .

BMC CANCER, 2022, 22 (01)

[47] Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A Review [J].

Koehler, Jens ;

Schuler, Martin .

ONKOLOGIE, 2013, 36 (09) :510-518

[48] Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Case Report, Literature Review, and Treatment Recommendations [J].

Kuykendall, Andrew ;

Chiappori, Alberto .

CANCER CONTROL, 2014, 21 (01) :67-73

[49] A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam [J].

Pham, Cam Phuong ;

Nguyen, Thi Thai Hoa ;

Do, Anh Tu ;

Nguyen, Tuan Khoi ;

Hoang, Thi Anh Thu ;

Le, Tuan Anh ;

Vuong, Dinh Thy Hao ;

Nguyen, Dac Nhan Tam ;

Dang, Van Khiem ;

Nguyen, Thi Oanh ;

Pham, Van Luan ;

Nguyen, Minh Hai ;

Vo, Thi Huyen Trang ;

Do, Hung Kien ;

Vu, Ha Thanh ;

Nguyen, Thi Thuy Hang ;

Pham, Van Thai ;

Trinh, Le Huy ;

Nguyen, Khac Dung ;

Nguyen, Hoang Gia ;

Truong, Cong Minh ;

Pham, Tran Minh Chau ;

Nguyen, Thi Bich Phuong .

BMC CANCER, 2024, 24 (01)

[50] A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027 [J].

Minegishi, Yuji ;

Yamaguchi, Ou ;

Sugawara, Shunichi ;

Kuyama, Shoichi ;

Watanabe, Satoshi ;

Usui, Kazuhiro ;

Mori, Masahide ;

Hataji, Osamu ;

Nukiwa, Toshihiro ;

Morita, Satoshi ;

Kobayashi, Kunihiko ;

Gemma, Akihiko .

BMC CANCER, 2021, 21 (01)

← 1 2 3 4 5 →